Skip to main content

emergent-biosolution-logo

US-based Emergent BioSolutions has completed proof-of concept manufacturing of a modified vaccinia Ankara (MVA) Ebola Zaire vaccine candidate (MVA EBOZ).

The MVA Ebola Zaire vaccine candidate is expected to be used in a Phase I clinical trial being supported by a grant from the Wellcome Trust and the UK Department for International Development.

{iframe}http://drugdelivery.pharmaceutical-business-review.com/news/emergent-completes-proof-of-concept-production-of-new-ebola-vaccine-170315-4533797{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.